Decitabine-primed Tandem CAR19/20 engineered T cells
Sponsors
Chinese PLA General Hospital, Han weidong
Conditions
Decitabine-primed Tandem CD19/CD20 CAR T CellsRefractory or Relapsed Aggressive r/r B-NHL With Huge Tumor BurdenRelapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Phase 1
Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden
NCT04553393
Start: 2020-09-09End: 2022-09-08Target: 80Updated: 2020-12-04
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Active, not recruitingNCT04697940
Start: 2021-04-15End: 2026-09-01Target: 33Updated: 2025-09-19